Literature DB >> 7720180

Long-term platinum excretion in patients treated with cisplatin.

R Schierl1, B Rohrer, J Hohnloser.   

Abstract

The purpose of this study was to determine long-term renal platinum excretion after chemotherapy with cisplatin. We examined urinary platinum concentrations in 23 men at 150-3022 days after anticancer treatment for testicular neoplasm. Spot urine samples were analyzed by voltammetry. This new, subtle method with a detection limit of 2 pg platinum allows determination of even the natural background level. Urinary platinum concentrations in our patients ranged between 0.74 and 77.24 micrograms/g creatinine, depending on the total delivered dose and follow-up period. Regression analysis of the data showed two phases of long-term renal platinum excretion, one occurring at between 150 and 900 days of follow-up and the other with an onset at 900 days after cisplatin administration (r1(2) = 0.82, r2(2) = 0.88). Two biological half-lives of 160 and 720 days were calculated. Our results show that urinary platinum concentrations determined at 8 years after cisplatin therapy are 40 times higher than the background level (up to 0.02 micrograms/g creatinine). Our findings on the long-term pharmacokinetics of this anticancer agent may facilitate further studies on sites of platinum storage in the human body as well as clinical studies on the late adverse effects of cisplatin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7720180     DOI: 10.1007/BF00685736

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  14 in total

1.  Acute and long-term nephrotoxicity of cis-platinum in man.

Authors:  S Groth; H Nielsen; J B Sørensen; A B Christensen; A G Pedersen; M Rørth
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 2.  Toxic effects of cis-dichlorodiammineplatinum(II) in man.

Authors:  D D Von Hoff; R Schilsky; C M Reichert; R L Reddick; M Rozencweig; R C Young; F M Muggia
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

3.  Urinary platinum in hospital personnel occupationally exposed to platinum-containing antineoplastic drugs.

Authors:  A S Ensslin; A Pethran; R Schierl; G Fruhmann
Journal:  Int Arch Occup Environ Health       Date:  1994       Impact factor: 3.015

4.  Kinetics of cis-dichlorodiammineplatinum.

Authors:  P E Gormley; J M Bull; A F LeRoy; R Cysyk
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

5.  Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.

Authors:  S J Harland; D R Newell; Z H Siddik; R Chadwick; A H Calvert; K R Harrap
Journal:  Cancer Res       Date:  1984-04       Impact factor: 12.701

6.  Noninvasive monitoring of drug biodistribution and metabolism: studies with intraarterial Pt-195m-cisplatin in humans.

Authors:  J Shani; J Bertram; C Russell; R Dahalan; D C Chen; R Parti; J Ahmadi; R A Kempf; T K Kawada; F M Muggia
Journal:  Cancer Res       Date:  1989-04-01       Impact factor: 12.701

Review 7.  Is cisplatin a human carcinogen?

Authors:  M H Greene
Journal:  J Natl Cancer Inst       Date:  1992-03-04       Impact factor: 13.506

8.  Peripheral sensory neuropathy and cisplatin chemotherapy.

Authors:  R I Roelofs; W Hrushesky; J Rogin; L Rosenberg
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

9.  Cisplatin-based combination chemotherapy for disseminated germ cell tumors: long-term follow-up.

Authors:  B J Roth; A Greist; P S Kubilis; S D Williams; L H Einhorn
Journal:  J Clin Oncol       Date:  1988-08       Impact factor: 44.544

10.  Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer.

Authors:  L H Einhorn; J Donohue
Journal:  Ann Intern Med       Date:  1977-09       Impact factor: 25.391

View more
  6 in total

1.  All half-lives are wrong, but some half-lives are useful.

Authors:  J G Wright; A V Boddy
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Occupational exposure to cytotoxic drugs in two UK oncology wards.

Authors:  E Ziegler; Howard J Mason; P J Baxter
Journal:  Occup Environ Med       Date:  2002-09       Impact factor: 4.402

3.  Urinary excretion of platinum from platinum industry workers.

Authors:  R Schierl; H G Fries; C van de Weyer; G Fruhmann
Journal:  Occup Environ Med       Date:  1998-02       Impact factor: 4.402

4.  Distribution of platinum group elements (Pt, Pd, Rh) in environmental and clinical matrices: Composition, analytical techniques and scientific outlook: Status report.

Authors:  T Hees; B Wenclawiak; S Lustig; P Schramel; M Schwarzer; M Schuster; D Verstraete; R Dams; E Helmers
Journal:  Environ Sci Pollut Res Int       Date:  1998       Impact factor: 4.223

Review 5.  Toxicity of Glutathione-Binding Metals: A Review of Targets and Mechanisms.

Authors:  Federico Maria Rubino
Journal:  Toxics       Date:  2015-01-26

6.  Diagnostic yield of colonoscopy surveillance in testicular cancer survivors treated with platinum-based chemotherapy: study protocol of a prospective cross-sectional cohort study.

Authors:  Berbel L M Ykema; Tanya M Bisseling; Manon C W Spaander; Leon M G Moons; Dorien van der Biessen-van Beek; Lisette Saveur; Martijn Kerst; Sasja F Mulder; Ronald de Wit; Danielle Zweers; Gerrit A Meijer; Jos H Beijnen; Iris Lansdorp-Vogelaar; Flora E van Leeuwen; Petur Snaebjornsson; Monique E van Leerdam
Journal:  BMC Gastroenterol       Date:  2021-02-12       Impact factor: 3.067

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.